Patent intelligence · US
US 10568871
Triazolone compounds and uses thereof
Triazolone compounds and uses thereof
Patent details — US 10568871
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 25, 2020
- Expiration
- Feb 20, 2040
- Applicant
- TEMPEST THERAPEUTICS, INC.
- Claims
- 20
- CPC classes
- A61K, A61K31/41, A61K31/4196, A61K31/4439
Quick answer
US 10568871 (Triazolone compounds and uses thereof) is held by TEMPEST THERAPEUTICS, INC.. Status: granted. Granted Feb 25, 2020. Expires Feb 20, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEMPEST THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/41, A61K31/4196, A61K31/4439, A61K31/506, A61P
More from TEMPEST THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12215093
Bicyclic carboxamides and methods of use thereof
granted -
US 11795156
Bicyclic carboxamides and methods of use thereof
granted -
US 11738009
Bicyclic compounds and their use in the treatment of cancer
granted -
US 11666557
Triazolone compounds and uses thereof
granted -
US 11638704
Bicyclic compounds and their use in the treatment of cancer
granted -
US 11472789
Bicyclic carboxamides and methods of use thereof
granted -
US 11066405
Bicyclic compounds and their use in the treatment of cancer
granted -
US 10968201
Bicyclic carboxamides and methods of use thereof
granted
Related coverage
Rise of Biosimilars in US: FDA Approval Trends & Market Impact
The article delves into the growing presence of biosimilars in the US market, focusing on FDA approval trends and their implications for drug pricing and patient access.
FDA Approves First Interchangeable Humira Biosimilar: Key Details
The FDA has approved the first interchangeable biosimilar to Humira, a significant milestone for patients with autoimmune conditions seeking affordable treatment alternatives.
Frequently asked questions
What is US patent 10568871?
US 10568871 (Triazolone compounds and uses thereof) is held by TEMPEST THERAPEUTICS, INC.. Status: granted. Granted Feb 25, 2020. Expires Feb 20, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10568871?
TEMPEST THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 10568871 expire?
Our index shows an expiration date of Feb 20, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.